The experimental coronavirus treatment Remdesivir has failed in its first randomized clinical trial, inadvertently released results showed Thursday, April 23, dampening expectations for the closely watched drug.
A draft summary went online briefly on the website of the World Health Organization (WHO) and was first reported by the Financial Times and Stat, which posted a screenshot.
But Gilead Sciences, the company behind the medicine; disputed how the now-deleted post had characterized the findings, saying the data showed a “potential benefit.”
The summary said the Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group.
Remdesivir treatment was stopped early in 18 patients because of side effects.
The authors said Remdesivir was “not associated with a difference in time to clinical improvement” compared to the control.
After a month, 13.9 percent of the patients on Remdesivir had died compared to 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
A spokesman for Gilead said: “We believe the post included inappropriate characterizations of the study,”; saying it was terminated early; due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive; though trends in the data suggest a potential benefit for Remdesivir, particularly among patients treated early in the disease,” the spokesman added.
The study does not represent the final word on the matter; there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously; was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
The drug, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly; as opposed to controlling the abnormal and often lethal autoimmune response it causes.
It mimics one of the four building blocks of RNA and DNA and gets absorbed into the virus’s genome; which in turn stops the pathogen from replicating.